ArticleCell death discovery2025
Therapeutic targeting of STING-IL6/STAT3 axis to inhibit osteoclastic niche formation and breast cancer bone metastasis.
Article in Cell death discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Despite numerous studies on tumor bone metastasis, little emphasis has been placed on the role of the formation of the osteoclastic premetastatic niche (OPN), and related genetic intervention targets are relatively scarce. Our data confirm the promoting effect of OPN formation on bone metastasis and demonstrate the existence of a vicious cycle between osteoclast differentiation and breast tumor cell proliferation through in vitro cell experiments. Moreover, we show that regulating Stimulator of Interferon Genes (STING) can break this cycle. However, both in vivo and in vitro experiments further indicate that STING intervention in OPN formation and breast tumor bone metastasis depends on IL6/STAT3, with a significant discount in the presence of IL-6 activation. In summary, these data not only highlight the important role of OPN but also emphasize STING-IL6/STAT3 as a crucial intervention target.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.